Literature DB >> 21172882

Outcome--adaptive randomization: is it useful?

Edward L Korn1, Boris Freidlin.   

Abstract

Outcome-adaptive randomization is one of the possible elements of an adaptive trial design in which the ratio of patients randomly assigned to the experimental treatment arm versus the control treatment arm changes from 1:1 over time to randomly assigning a higher proportion of patients to the arm that is doing better. Outcome-adaptive randomization has intuitive appeal in that, on average, a higher proportion of patients will be treated on the better treatment arm (if there is one). In both the randomized phase II and phase III settings with a short-term binary outcome, we compare outcome-adaptive randomization with designs that use 1:1 and 2:1 fixed-ratio randomizations (in the latter, twice as many patients are randomly assigned to the experimental treatment arm). The comparisons are done in terms of required sample sizes, the numbers and proportions of patients having an inferior outcome, and we restrict attention to the situation in which one treatment arm is a control treatment (rather than the less common situation of two experimental treatments without a control treatment). With no differential patient accrual rates because of the trial design, we find no benefits to outcome-adaptive randomization over 1:1 randomization, and we recommend the latter. If it is thought that the patient accrual rates will be substantially higher because of the possibility of a higher proportion of patients being randomly assigned to the experimental treatment (because the trial will be more attractive to patients and clinicians), we recommend using a fixed 2:1 randomization instead of an outcome-adaptive randomization.

Entities:  

Mesh:

Year:  2010        PMID: 21172882      PMCID: PMC3056658          DOI: 10.1200/JCO.2010.31.1423

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  20 in total

1.  Optimal adaptive designs for binary response trials.

Authors:  W F Rosenberger; N Stallard; A Ivanova; C N Harper; M L Ricks
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

2.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

Review 3.  Multi-arm clinical trials of new agents: some design considerations.

Authors:  Boris Freidlin; Edward L Korn; Robert Gray; Alison Martin
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

4.  Randomized clinical trials. Perspectives on some recent ideas.

Authors:  D P Byar; R M Simon; W T Friedewald; J J Schlesselman; D L DeMets; J H Ellenberg; M H Gail; J H Ware
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

5.  Allocation of subjects in medical experiments.

Authors:  M C Weinstein
Journal:  N Engl J Med       Date:  1974-12-12       Impact factor: 91.245

6.  Optimal allocation for the comparison of proportions.

Authors:  E Brittain; J J Schlesselman
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  A general inefficacy interim monitoring rule for randomized clinical trials.

Authors:  Boris Freidlin; Edward L Korn; Robert Gray
Journal:  Clin Trials       Date:  2010-04-27       Impact factor: 2.486

8.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

9.  Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.

Authors:  Swati Biswas; Diane D Liu; J Jack Lee; Donald A Berry
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

10.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

View more
  61 in total

Review 1.  Role of randomized phase III trials in an era of effective targeted therapies.

Authors:  Manish R Sharma; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  Optimal and lead-in adaptive allocation for binary outcomes: a comparison of Bayesian methodologies.

Authors:  Roy T Sabo; Ghalib Bello
Journal:  Commun Stat Theory Methods       Date:  2016-04-08       Impact factor: 0.893

3.  Are outcome-adaptive allocation trials ethical?

Authors:  Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

4.  A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.

Authors:  Vinay K Puduvalli; Jing Wu; Ying Yuan; Terri S Armstrong; Elizabeth Vera; Jimin Wu; Jihong Xu; Pierre Giglio; Howard Colman; Tobias Walbert; Jeffrey Raizer; Morris D Groves; David Tran; Fabio Iwamoto; Nicholas Avgeropoulos; Nina Paleologos; Karen Fink; David Peereboom; Marc Chamberlain; Ryan Merrell; Marta Penas Prado; W K Alfred Yung; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

5.  Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Natl Cancer Inst       Date:  2017-06-01       Impact factor: 13.506

Review 6.  Precision medicine needs randomized clinical trials.

Authors:  Everardo D Saad; Xavier Paoletti; Tomasz Burzykowski; Marc Buyse
Journal:  Nat Rev Clin Oncol       Date:  2017-02-07       Impact factor: 66.675

7.  Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.

Authors:  Chul Kim; Giuseppe Giaccone
Journal:  Ann Transl Med       Date:  2016-12

8.  Adaptive clinical trial designs in oncology.

Authors:  Yong Zang; J Jack Lee
Journal:  Chin Clin Oncol       Date:  2014-12

9.  Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.

Authors:  P Thall; P Fox; J Wathen
Journal:  Ann Oncol       Date:  2015-05-15       Impact factor: 32.976

10.  Commentary on Hey and Kimmelman.

Authors:  J Jack Lee
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.